AbbVie and Tentarix collaborate on oncology and immunology treatments
Betsy Goodfellow | February 23, 2024 | News story | Research and Development | AbbVie, Oncology, collaboration, immunology
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.
The collaboration is intended to utilise AbbVie’s expertise in oncology and immunology with Tentarix’s proprietary Tentacles platform.
Under the terms of this agreement, Tentarix will receive upfront payment options with a total of $64m from AbbVie for the two programmes.
Jonathon Sedgwick PhD, senior vice president and global head of discover research at AbbVie, commented: “Oncology and immunology are two of our key strategic growth areas where we are pursuing novel technologies that aim to deliver transformative therapies, which address unmet patient needs. This strategic partnership complements our ongoing efforts in developing novel biologics, potentially to expand our oncology and immunology portfolios with conditionally-active multi-specific molecules.”
Don Santel, interim chief executive officer at Tentarix Biotherapeutics, added: “We are excited to join forces with AbbVie to help accelerate cutting-edge, conditionally-active therapeutic programmes towards clinical applications for patients in need. This collaboration adds to our portfolio of internal and external pipeline programmes and is a strong validation of our approach in understanding and targeting complex immune interactions that drive cancers and inflammatory diseases.”
Betsy Goodfellow
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
